{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:06:16Z","timestamp":1794027976770,"version":"4.8.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2020\u20130741"],"award-info":[{"award-number":["FAI-2020\u20130741"]}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Professor Nanna Svartz Foundation","award":["2021\u201300436"],"award-info":[{"award-number":["2021\u201300436"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Region Stockholm","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Substantial proportions of patients with SLE report poor health-related quality of life (HRQoL). Our objective was to investigate the impact of neuropsychiatric involvement (NP) in SLE on patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed data from four phase III trials (BLISS-52, BLISS-76, BLISS-SC, EMBRACE; N\u2009=\u20092968). The NPSLE group comprised individuals with NP-BILAG A\/B\/C\/D or score in any descriptor of the NP-SLEDAI-2K at baseline (N\u2009=\u2009350), while the non-NPSLE group consisted of patients with NP-BILAG E (N\u2009=\u20092618). HRQoL was assessed with the SF-36, EQ-5D-3L, and FACIT-F. Full health state (FHS) was defined as \u2018no problems\u2019 in all EQ-5D dimensions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NPSLE patients reported lower scores in the SF-36 physical and mental component summary compared with the non-NPSLE population [mean (s.d.): 35.7 (9.1) vs 39.6 (9.6); P\u2009&amp;lt;\u20090.001 and 37.3 (12.1) vs 41.4 (11.0); P\u2009&amp;lt;\u20090.001, respectively]. NPSLE patients also exhibited impaired HRQoL in all EQ-5D dimensions compared with non-NPSLE patients (P\u2009&amp;lt;\u20090.05 for all). A substantially lower proportion of NPSLE patients experienced FHS in comparison with the non-NPSLE group (3.3% vs 14.5%; P\u2009&amp;lt;\u20090.001). NPSLE was associated with severe fatigue [23.8 (12.2) vs 31.5 (11.6); P\u2009&amp;lt;\u20090.001]. Notably, our findings revealed no discernible distinctions between active and inactive NPSLE patients with regard to SF-36, EQ-5D, FHS or FACIT-F scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NP in patients with SLE has a detrimental effect on HRQoL experience and is associated with severe fatigue, regardless of the degree of neuropsychiatric disease activity. Early intervention is warranted in NPSLE patients to enhance long-term HRQoL experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae216","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:17:20Z","timestamp":1712236640000},"page":"2494-2502","source":"Crossref","is-referenced-by-count":16,"title":["Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity"],"prefix":"10.1093","volume":"63","author":[{"given":"Dionysis","family":"Nikolopoulos","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nursen","family":"Cetrez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-9471","authenticated-orcid":false,"given":"Julius","family":"Lindblom","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-7447","authenticated-orcid":false,"given":"Leonardo","family":"Palazzo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Enman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden"},{"name":"Faculty of Medicine and Health, Department of Rheumatology, \u00d6rebro University , \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2024091608262566500_keae216-B1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0961203320908932","article-title":"Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the \u2018Attikon\u2019 cohort","volume":"29","author":"Nikolopoulos","year":"2020","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/1744666X.2021.1899810","article-title":"Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives","volume":"17","author":"Nikolopoulos","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2024091608262566500_keae216-B3","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/0961203318772021","article-title":"Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study","volume":"27","author":"Ahn","year":"2018","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2019-216150","article-title":"Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach","volume":"79","author":"Hanly","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024091608262566500_keae216-B5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.41070","article-title":"Peripheral nervous system disease in systemic lupus erythematosus: results from an international inception cohort study","volume":"72","author":"Hanly","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024091608262566500_keae216-B6","first-page":"322","author":"Strand"},{"key":"2024091608262566500_keae216-B7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0961203313502109","article-title":"Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain","volume":"22","author":"Waldheim","year":"2013","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1177\/0961203312441980","article-title":"Development of a conceptual model of health-related quality of life for systemic lupus erythematosus from the patient\u2019s perspective","volume":"21","author":"Gallop","year":"2012","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B9","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/0961203310378668","article-title":"Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study","volume":"19","author":"McElhone","year":"2010","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B10","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1093\/rheumatology\/keaa909","article-title":"Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE","volume":"60","author":"Borg","year":"2021","journal-title":"Rheumatology"},{"key":"2024091608262566500_keae216-B11","first-page":"4752","article-title":"Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus","volume":"61","author":"Emamikia","year":"2022","journal-title":"Rheumatol (United Kingdom)"},{"key":"2024091608262566500_keae216-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9061813","article-title":"Use of antimalarial agents is associated with favourable physical functioning in patients with systemic lupus erythematosus","volume":"9","author":"Gomez","year":"2020","journal-title":"J Clin Med"},{"key":"2024091608262566500_keae216-B13","first-page":"1706","article-title":"How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?","volume":"32","author":"Jolly","year":"2005","journal-title":"J Rheumatol"},{"key":"2024091608262566500_keae216-B14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1212\/WNL.0000000000002564","article-title":"Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity","volume":"86","author":"Berrigan","year":"2016","journal-title":"Neurology"},{"key":"2024091608262566500_keae216-B15","first-page":"1237","article-title":"Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis","volume":"49","author":"Rudick","year":"1992","journal-title":"JAMA Neurol"},{"key":"2024091608262566500_keae216-B16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2024091608262566500_keae216-B17","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024091608262566500_keae216-B18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two\u2013week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024091608262566500_keae216-B19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two\u2013week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024091608262566500_keae216-B20","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2024091608262566500_keae216-B21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): i. Conceptual Framework and Item Selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2024091608262566500_keae216-B22","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume-title":"Health Qual Life Outcomes","author":"Webster","year":"2003"},{"key":"2024091608262566500_keae216-B23","author":"Euroqol Research Foundation [ERF]","year":"2018"},{"key":"2024091608262566500_keae216-B24","doi-asserted-by":"crossref","first-page":"e000373","DOI":"10.1136\/lupus-2019-000373","article-title":"Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review","volume":"7","author":"Strand","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2024091608262566500_keae216-B25","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine (Phila Pa 1976)"},{"key":"2024091608262566500_keae216-B26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3899\/jrheum.100799","article-title":"Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial","volume":"38","author":"Lai","year":"2011","journal-title":"J Rheumatol"},{"key":"2024091608262566500_keae216-B27","doi-asserted-by":"crossref","first-page":"1092325","DOI":"10.3389\/fmed.2022.1092325","article-title":"EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus","volume":"9","author":"Lindblom","year":"2022","journal-title":"Front Med"},{"key":"2024091608262566500_keae216-B28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/jcm11020340","article-title":"Patient-reported outcomes in systemic lupus erythematosus. can lupus patients take the driver\u2019s seat in their disease monitoring?","volume":"11","author":"Parodis","year":"2022","journal-title":"J Clin Med"},{"key":"2024091608262566500_keae216-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S369584","article-title":"Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: insights from clinical trials and real-world evidence","volume":"14","author":"Gomez","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"2024091608262566500_keae216-B30","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S2665-9913(21)00387-8","article-title":"Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 tr","volume":"4","author":"Strand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024091608262566500_keae216-B31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/acr.23788","article-title":"Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment","volume":"71","author":"Strand","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2024091608262566500_keae216-B32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0961203317716319","article-title":"Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus","volume":"27","author":"Piga","year":"2018","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B33","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/0961203317694262","article-title":"Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life","volume":"26","author":"Monahan","year":"2017","journal-title":"Lupus"},{"key":"2024091608262566500_keae216-B34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/art.22305","article-title":"Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study","volume":"56","author":"Hanly","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024091608262566500_keae216-B35","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acr.23509","article-title":"Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study","volume":"70","author":"Hanly","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2024091608262566500_keae216-B36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024091608262566500_keae216-B37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.41070","article-title":"Peripheral nervous system disease in Systemic Lupus Erythematosus: results from an international, inception cohort study","volume":"72","author":"Hanly","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2024091608262566500_keae216-B38","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/art.39111","article-title":"Mood disorders in systemic lupus erythematosus: results from an international inception cohort study","volume":"67","author":"Hanly","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024091608262566500_keae216-B39","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1002\/art.38106","article-title":"Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study","volume":"65","author":"Hanly","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024091608262566500_keae216-B40","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1093\/rheumatology\/kead140","article-title":"Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State","volume":"62","author":"Hua","year":"2023","journal-title":"Rheumatology"},{"key":"2024091608262566500_keae216-B41","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1093\/rheumatology\/keab080","article-title":"EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus","volume":"60","author":"Lindblom","year":"2021","journal-title":"Rheumatology (United Kingdom)"},{"key":"2024091608262566500_keae216-B42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"Van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024091608262566500_keae216-B43","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","author":"Parodis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024091608262566500_keae216-B44","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.3390\/jcm10163566","article-title":"Fatigue in systemic lupus erythematosus and rheumatoid arthritis: a comparison of mechanisms, measures and management","volume":"10","author":"Dey","year":"2021","journal-title":"J Clin Med"},{"key":"2024091608262566500_keae216-B45","doi-asserted-by":"crossref","first-page":"111975","DOI":"10.1016\/j.bbr.2019.111975","article-title":"Shared microglial mechanisms underpinning depression and chronic fatigue syndrome and their comorbidities","volume":"372","author":"Chaves-Filho","year":"2019","journal-title":"Behav Brain Res"},{"key":"2024091608262566500_keae216-B46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/ard-2022-223506","article-title":"Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus","volume":"82","author":"Nikolopoulos","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024091608262566500_keae216-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2021.651249","article-title":"Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus","volume":"8","author":"Gomez","year":"2021","journal-title":"Front Med"},{"key":"2024091608262566500_keae216-B48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/BOR.0000000000000655","article-title":"Update on the pathogenesis of central nervous system lupus","volume":"31","author":"Nikolopoulos","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2024091608262566500_keae216-B49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/jcm12010227","article-title":"Persistence of depression and anxiety despite short-term disease activity improvement in patients with systemic lupus erythematosus: a single-centre, prospective study. J Clin Med 2022;11:4316. Erratum in:","volume":"12","author":"Nikoloudaki","year":"2023","journal-title":"J Clin Med"},{"key":"2024091608262566500_keae216-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2023-003297","article-title":"Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"9","author":"Parodis","year":"2023","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae216\/57726532\/keae216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2494\/59135598\/keae216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2494\/59135598\/keae216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T04:27:54Z","timestamp":1726460874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2494\/7641537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,5]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae216","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,5]]}}}